CADTH Symposium Travel Award Program for Students and Patient Group Representatives – apply by 10-Dec-2018

CADTH is pleased to announce the 2019 CADTH Symposium Travel Award Program for students and patient group representatives.

Since 2007, CADTH has provided financial support toward conference-related costs for more than 335 student and patient group representatives as part of our commitment to making this important event accessible to all health care stakeholders.

This year, eligible students and patient group representatives can receive up to $2,000 to offset registration, travel, food, accommodation, and other conference-related expenses.

For Students

The 2019 CADTH Symposium offers an excellent opportunity to share your research, learn about the latest advancements in health technology assessment, and interact with peers from across the country as well as leading Canadian and international experts. If you’re a full-time undergraduate or graduate student attending a degree-granting institution in Canada, and taking courses in a field relevant to CADTH’s work, we invite you to apply for a travel award.

For Patient Group Representatives

It’s important that your voice is heard. If you work for a not-for-profit, patient-related organization, or a citizen’s organization interested in health policy, we invite you to apply for a travel award.

How to Apply

Step 1: Review the 2019 CADTH Symposium Travel Award Program Criteria.
Step 2: Complete and submit the 2019 Travel Awards Application form to CADTH by December 10, 2018.

Travel award decisions will be made by the end of January 2019, and awards will be issued to successful applicants by the end of March 2019.

Reminder: The Abstract Submission Deadline for the 2019 CADTH Symposium is October 26, 2018. Priority will be given to Travel Award applicants who have submitted an abstract for the 2019 CADTH Symposium.

If you have questions about the 2019 CADTH Symposium, or the Travel Award Program, please contact us at symposium@cadth.ca. We’re looking forward to seeing you in Edmonton in 2019.

About CADTH

CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Learn more at: www.cadth.ca.

Advertisements

Webinar: Pain Community Research Priorities with Dr. Christine Chambers, 03-Oct-2018

This is your opportunity to contribute to the CIHR Institute of Musculoskeletal Health and Arthritis (IMHA) priorities for 2019-2022! Please join one of a series of Webinars being hosted by the Scientific Director of IMHA, Professor Karim Khan, and leaders of the IMHA research community. Here are the details for the webinar that will focus on priorities for Pain Research.

Pain Community Research Priorities with Dr. Christine Chambers
Wednesday, October 03, 2018 at NOON Eastern Time
Mark the time in your calendar!

*Click here to enter the webinar on the day*

 

Agenda for the session:

12:00 PM – 12:05 PM Introduction to the webinar – Tanya Gallant, IMHA Assistant Director
12:05 PM – 12:15 PM IMHA priority setting process. Why are we having webinars and what can you do to influence IMHA priorities? – Prof. Karim Khan, IMHA Scientific Director
12:15 PM – 12:30 PM Pain Research. What are the current priorities? What needs to be included? Dr. Christine Chambers
12:30 PM – 12:50 PM Open Forum – opportunity for those on the webinar to contribute via the webinar service and Twitter.
12:50 PM – 12:59 PM Close of the webinar and next steps

If you can’t make it live, we will make the recording available afterwards transcribed into English and French. Use this email address – imha-iala@cihr-irsc.gc.ca – to send in your contributions until Friday, October 19, 2018.

For more on IMHA and its 2014-2018 priorities, see this link: http://www.cihr-irsc.gc.ca/e/27024.html

Webinars will be scheduled for each of our priority and research areas. If you’d like to be notified about our other webinars, please subscribe to our newsletter by emailing imha-iala@cihr-irsc.gc.ca.

Sincerely,

Christine T. Chambers, PhD RPsych
Institute Advisory Board (IAB) Member, CIHR IMHA

Congratulations to Shane Sinclair from the University of Calgary on the receipt of a C17 Research Network grant targeted at conceptualizing and operationalizing compassion

Grant title: Conceptualizing and Operationalizing Compassion in Pediatric Oncology: The Development of a Patient, Family Member and Healthcare Provider Informed Theoretical Model

Lay abstract:  Compassion is a key component of high quality healthcare. While children and family members increasingly expect compassion and healthcare providers desire to provide it, providing and receiving compassion in the pediatric oncology settings is a growing challenge. Although Canadian Pediatric Society guidelines state that “It is essential that every team member…provide compassionate care that meets or exceeds parents’ expectations,” and the Hospice Palliative Care Association attests that “Pediatric hospice palliative care is provided by an interdisciplinary team of competent and compassionate formal caregivers who work collaboratively with the child and family,” no studies have defined and operationalized compassion within a pediatric setting.

This study will develop a clinically informed, patient and family centered, theoretical model of compassion from the perspective of children living within advanced cancer, their parents and healthcare providers. The aim of this study is to conceptualize and operationalize compassion from the perspective of individuals who are exposed and are challenged to address suffering on a frequent basis. This study will generate a model illustrating the key care domains of compassionate care that healthcare providers need to be cognizant of in order to optimally deliver compassion. While compassion is particularly salient to this population we believe the findings will be of relevance across oncology, BMT and hematology populations.

 

Congratulations to Jason Berman from IWK on the receipt of a C17 Research Network grant targeting neuroblastoma

Grant title: The Microenvironment as a Therapeutic Target in High Risk Neuroblastoma

Lay abstract: Neuroblastoma is one of the most deadly cancers in children. While advances in treatment have made some improvements to survival, more than half of children will still die of disease. When neuroblastoma cells from the initial tumour move to another spot in the body and form another tumour, this is called metastasis and is particularly deadly. Thus, being able to stop cancer cells from spreading to organs like the bone, bone marrow and brain is critical to impacting survival of these vulnerable children. The spread of cancer cells is not only dependent on the cancer cell itself, but also on factors in the surrounding environment, known as the tumour microenvironment. Determining how these factors contribute to the spread of neuroblastoma and either increasing or decreasing these levels could improve current neuroblastoma treatment. We have developed approaches to transplant human cancer cells into zebrafish embryos, which are see-through and have similar cells and organs as humans, providing an environment not dissimilar from what occurs when these cancer cells arise in children. We have further “humanized” these zebrafish by altering them to express certain human factors produced by cells found around cancer cells that may contribute to their movement. We will put human neuroblastoma cells into zebrafish and determine which factors outside and inside the cells affect where these cells travel. Information from these studies will provide guidance as to what factors to block or increase to prevent neuroblastoma spread and improve outcome.

 

Congratulations to Ted Gerstle from the Sick Kids Research Institute on the receipt of a 100% Fund grant targeting rhabdomyosarcoma

Grant title: MRI-guided High Intensity Focused Ultrasound-controlled hyperthermia to activate thermosensitive liposomal doxorubicin to treat rhabdomyosarcoma (RMS) in a mouse model

Lay abstract: Rhabdomyosarcoma (RMS), the most common muscle tumor of childhood, can be difficult to treat because of the side-effects of radiation and surgery in certain locations as well as the long term toxicity of chemotherapy agents. Magnetic Resonance Imaging (MRI) can be used to guide high intensity focused ultrasound (HIFU) beams to warm the tissue at the tumor up to a temperature of 42C. We will combine this mild hyperthermia with administration of an encapsulated chemotherapy drug (doxorubicin) specifically designed to release the drug in tissue which has been heated to 42C. We will create rhabdomyosarcoma tumors in mice and treat them using the combined MR guided HIFU and thermosensitivie doxorubicin formulation. We hypothesize that this combined approach could reduce tumor growth and minimize the toxicity of the drug by focusing its release at the tumor and minimizing systemic drug levels. This preclinical project would form the basis for the translation of the use of MRgHIFU and thermosensitive doxorubicin treatment into the pediatric oncology clinic, offering a treatment that could prolong life for patients with rhabdomyosarcoma and significantly reduce morbidity. This approach would be safer than current therapy and would be an exciting translation of MRgHIFU and liposomal doxorubicin from adult to pediatric therapy expanding treatment options for this challenging disease.

Funding partners: Fight Like Mason Foundation, Team Naomi, Team Finn and Coast-to-Coast Against Cancer. 100% Fund grants are adjudicated and administered by the C17 Research Network.


Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds. Coast-to-Coast Against Cancer is partnering with Phoebe Rose Rocks Foundation, Fight Like Mason Foundation, Team Naomi, and Team Finn to help fund research for children and teens who do not, yet, have their cure.  The purpose of The 100% Fund is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Projects can range from discovery to clinical trials, but must be targeted at delivering a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

Congratulations to Sumit Gupta from The Hospital for Sick Children on the receipt of a 100% Fund Grant targeting infant ALL

Grant title: The characterization of previously undetected MLL gene abnormalities in infant ALL

Lay Abstract: Infant acute lymphoblastic leukemia (ALL) is a rare, but devastating disease in babies less than 1 year old. For babies with high risk features, including an abnormality in the MLL gene (MLL-r), only one in five survive. Normally MLL-r is detected in a laboratory using FISH technology, the current standard. We encountered two babies who were found not to have MLL-r by FISH, but abnormalities were discovered using next generation sequencing (NGS), a newer technology. Identification of MLL-r is extremely important because studies show babies with high risk infant ALL have better outcomes using more intense therapy; failing to identify MLL-r may result in under-treatment. Also, new drugs have recently been developed targeting the MLL gene. If MLL-r is not detected, patients are not eligible for these potentially beneficial medications. We suspect that there are other infants with MLL-r that have not been detected by FISH. Using samples from patients with infant ALL and normal MLL genes by FISH, we will determine how often this happens by using NGS. If we find a significant number of hidden MLL-r, doctors will potentially have to change the way they detect such abnormalities so that patients receive appropriate therapy and optimal outcomes.

Funding partners:  Phoebe Rose Rocks and Coast-to-Coast Against Cancer. 100% Fund grants are adjudicated and administered by the C17 Research Network.


Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds. Coast-to-Coast Against Cancer is partnering with Phoebe Rose Rocks Foundation, Fight Like Mason Foundation, Team Naomi, and Team Finn to help fund research for children and teens who do not, yet, have their cure.  The purpose of The 100% Fund is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Projects can range from discovery to clinical trials, but must be targeted at delivering a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

CIHR Request for Applications: Transitions in Care Team Grant | Subventions d’équipe Transitions dans les soins

CIHR, on behalf of the Transitions in Care (TiC) multi-Institute strategic initiative and its associated Institutes, is pleased to announce the launch of the TiC Team Grants. The focus of this funding opportunity is to support inter-disciplinary teams that are poised and ready to address transition in care challenges to optimize patient outcomes.  The grants will provide funds to implement, evaluate, spread, and scale pragmatic solutions to problems associated with transitions in care from a clinical, health care and/or health system perspective.

Research Areas

This funding opportunity will support applications centered on the intersection of two or more TiC focus areas.

 Application Streams

There are two (2) application streams for this funding opportunity:

  • Stream 1: PHSI solutions for transitions in care gaps
  • Stream 2: eHIPP solutions for transitions in care gaps

 Anticipated timelines

  • Program Launch: August 30, 2018
  • Application Deadline: January 24, 2019
  • Notice of Decision: April 2019
  • Funding Start Date: April 1, 2019

Funds Available

  • The total CIHR amount available for this funding opportunity is $9.6 million enough to fund approximately ten (10)
  • The maximum CIHR amount per grant is $240,000 per year for up to four (4) years for a total of$960,000 per grant.
  • Applicants must secure, by the application deadline, partnership contributions equivalent to a minimum of 30% of the total grant amount requested, with a minimum of half of the amount representing a cash contribution (i.e., a total of $288,000 partner match required per grant with minimum of $144,000 as a cash contribution per grant), for a total grant value of up to $1.248 million per grant over four (4) years.

Partner Linkage Tool

CIHR has launched an on-line linkage tool designed to assist researchers and other stakeholders in identifying and connecting with potential partners to develop their projects. The goal of this tool is to allow potential applicants, knowledge users and partners with the ability to connect to see if synergies can be leveraged in the development of research ideas and applications. This tool should be completed by organizations (e.g. health information technology companies, health authorities, hospitals, etc.), researchers and other individuals (patients, health care professionals, etc.) who have an interest in connecting with others in relation to the Transitions in Care Team Grants . The information provided will be posted on CIHR’s web page.

To learn more

The complete funding opportunity is now live on ResearchNet.

Contact

CIHR Contact Centre
Toll Free: 1-888-603-4178
support@cihr-irsc.gc.ca

 


Appel de demandes : subventions d’équipe Transitions dans les soins

Les IRSC, au nom de l’initiative stratégique interinstituts Transitions dans les soins (TS) et de ses instituts associés, sont heureux d’annoncer le lancement des subventions d’équipe TS. Cette possibilité de financement vise essentiellement à soutenir des équipes interdisciplinaires qui sont disposées et prêtes à optimiser les résultats pour les patients des transitions dans les soins. Les fonds octroyés permettront de mettre en œuvre, d’évaluer, de diffuser et de mettre à l’échelle des solutions pragmatiques aux problèmes liés aux transitions dans les soins selon une perspective clinique, de soins de santé et/ou de système de santé.

Domaines de recherche

Cette possibilité de financement vise à soutenir des projets centrés sur le recoupement d’au moins deux des secteurs d’intervention privilégiés de l’initiative TS.

 Volets de recherche

La présente possibilité de financement comporte deux volets :

  • Volet 1 : solutions PASS pour les transitions dans les soins
  • Volet 2 : solutions PPIC pour les transitions dans les soins

 Échéancier prévu

  • Lancement du programme : 30 août 2018
  • Date limite de présentation des demandes : 24 janvier 2019
  • Diffusion de l’avis de décision : avril 2019
  • Date du début du financement : 1er avril 1 2019

Fonds disponibles

  • Le montant total disponible dans le cadre de cette possibilité de financement est de 9,6 millions de dollars, ce qui devrait permettre de financer une dizaine de subventions.
  • La somme maximale accordée par les IRSC par subvention et par année est de 240 000 $ pour au plus quatre ans, soit un total de 960 000 $ par subvention.
  • Les candidats doivent, d’ici la date limite de présentation des demandes, obtenir une contribution partenariale équivalant à un minimum de 30 % de la valeur totale de la subvention demandée, et au moins la moitié de cette somme doit être une contribution en espèces (c.-à-d. que 288 000 $ au total par subvention doivent provenir de partenaires, dont un minimum de 144 000 $ en espèces), pour un total de 1 248 000 $ par subvention pendant quatre ans.

Outil d’établissement de liens

Les IRSC ont lancé un outil d’établissement de liens en ligne conçu pour aider les chercheurs et autres parties concernées à échanger avec des partenaires éventuels en vue de développer des projets.  L’objectif de cet outil est de permettre aux utilisateurs de connaissances, partenaires et candidats potentiels d’entrer en contact afin de tirer parti des synergies ainsi créées pour pousser plus loin leurs idées de recherche. Cet outil devrait être utilisé par des organisations (p. ex. sociétés de technologie de l’information sur la santé, autorités sanitaires, hôpitaux), des chercheurs et d’autres personnes (patients, professionnels de la santé, etc.) qui souhaitent établir des contacts relativement aux subventions d’équipe de l’initiative Transitions dans les soins. L’information fournie sera publiée sur une page Web des IRSC.

Pour en savoir plus

La version intégrale de la possibilité de financement est maintenant accessible en ligne dans RechercheNet.

Renseignements

Centre de contact des IRSC
Numéro sans frais : 1-888-603-4178
soutien@cihr-irsc.gc.ca

CADTH pan-Canadian Oncology Drug Review (pCODR): invitation to patient groups and registered clinicians to provide input on Dinutuximab (Unituxin) for neuroblastoma – submit using templates by Oct 15

The CADTH pan-Canadian Oncology Drug Review (pCODR) is anticipating that a submission will be made for Dinutuximab (Unituxin) for Neuroblastoma.  The manufacturer has indicated that it will seek funding for dinutuximab (Unituxin) to be used in combination with GM-CSF, IL-2 and Retinoic acid (RA) for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multi-agent, multimodality therapy.

The targeted deadline for receiving patient group input and registered clinician input on crizotinib (Xalkori)for ROS1-positive advanced NSCLC, dinutuximab (Unituxin) for neuroblastoma and palbociclib (Ibrance) in combination with fulvestrant for MBC is October 15, 2018  by 5:00 p.m. Eastern Time. This date is tentative and will be confirmed on the CADTH website once the submission has been filed by the manufacturer.

Templates to Complete

Patient group submissions can be made through the CADTH website once the submission has been filed by the manufacturer using the Patient Input Template for CADTH CDR and pCODR Programs.

Registered clinician submissions can be made through the CADTH website once the submission has been filed by the manufacturer by using the designated:

Patient groups and clinicians that have not yet registered with pCODR and would like to provide input are invited to visit pCODR Registration for details on registration.

About CADTH

CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Learn more at: www.cadth.ca.

52 buildings and landmarks to go GOLD on Friday for Childhood Cancer Awareness month. Click to see the list for a GOLD building near you.

50 buildings and landmarks from the BC Legislature Building in Victoria to the St. John’s City Hall in Newfoundland (plus two international sites) will illuminate in golden light on September 1 in honour of  the first day of Childhood Cancer Awareness month.
Airdrie City Hall 400 Main Street SE Airdrie AB
Airdrie Fountain 400 Main Street SE Airdrie AB
Arts Commons 205 8th Ave Calgary AB
McMahon Stadium 1817 Crowchild Trail NW Calgary AB
Reconciliation Bridge 12 4 St NE Calgary AB
Calgary Tower 101 9th Ave SW Calgary AB
ATB Place 10025 Jasper Ave. NW Edmonton AB
High Level Bridge 109th St. Edmonton AB
Telus World of Science 11211 142nd St. NW Edmonton AB
Town Square Gazebo 10209-109 Street Fairview AB
Sylvan Lake Lighthouse 5220 Lakeshore Drive Sylvan Lake AB
Coquitlam City Hall PineTree Way Columns 3000 Guildford Way Coquitlam BC
Coquitlam Skytrain Guideway Pillars 1205 Pinetree Way Coquitlam BC
Fountain at Lafarge Lake 1205 Pinetree Way Coquitlam BC
Spirit of Sail 200 Bernard Ave. Kelowna BC
add British Columbia Childrens Hospital 4480 Oak St. Vancouver BC
BC Place 777 Pacific Boulevard Vancouver BC
Olympic Cauldron lights 1055 Canada Place Vancouver BC
Sails of Light 99 Canada Place Vancouver BC
Telus World of Science 1455 Quebec St. Vancouver BC
Vancouver City Hall 453 W 12th Ave Vancouver BC
BC Legislature 501 Belleville St. Victoria BC
Royal BC Museum 675 Belleville St Victoria BC
220 Portage Ave. Building 220 Portage Ave. Winnipeg MB
RBC Convention Centre 375 York Ave. Winnipeg MB
Richardson Centre 1 Lombard Place Winnipeg MB
WINNIPEG sign at the forks 85 Israel Asper Way Winnipeg MB
add St. John’s City Hall 10 New Gower St. St. John’s NL
Confederation Building 100 Parkway St. John’s NL
Halifax City Hall 1841 Argyle St Halifax NS
Burlington Pier 1400 Lakeshore Rd Burlington ON
Cambridge City Hall Sign 50 Dickson St. Cambridge ON
Belmont Fire Hall Bell Tower 206 Caesar Road Central Elgin ON
add Hamilton City Hall 71 Main St. West Hamilton ON
J.Allyn Taylor Building 391 Wellington St. London ON
London City Hall 300 Dufferin Avenue London ON
London Convention Center 300 York St. London ON
London Life Building 255 Dufferin Ave. London ON
London Sifton Properties on Dufferin 200 Queens Ave London ON
Walter J. Blackburn Memorial Fountain 70 Riverside Dr. London ON
Skylon Tower 5200 Robinson St. Niagara Falls ON
The Falls at Niagara 6650 Niagara Parkway Niagara Falls ON
Oshawa City Hall 50 Center St. South Oshawa ON
CN Tower 301 Front St. W Toronto ON
Royal Bank Plaza “The Zipper” 200 Bay St. Toronto ON
TMX Exchange Opening Bell 130 King St. West Toronto ON
Toronto City Hall Towers 100 Queen St. West Toronto ON
Toronto Mayoral Proclamation 100 Queen St. West Toronto ON
TORONTO Paralympic Games Sign 100 Queen St. West Toronto ON
Welland Lift Bridge 13 25 W Main St Welland ON
Prairie Winds 100 Spadina Cres E Saskatoon SK
Jet D’eau 1207 Promanade du Lac Geneva

Switzerland

Peace Bridge 1 Peace Bridge Buffalo NY
Led by the Advocacy for Canadian Childhood Oncology Research Network (Ac2orn) and Director of Awareness with the Coalition Against Childhood Cancer, Neal Rourke.

Nous avons besoin de votre contribution. Ensemble nous pouvons faire une différence pour la douleur chez les enfants ! [French version of SKIP survey.]

Les membres de notre centre ont travaillé en étroite collaboration avec nos amis de l’Association canadienne des centres de santé pédiatriques (CAPHC) et plusieurs autres à travers le Canada et au-delà sur une proposition pour soutenir un nouveau réseau nommé « Solutions for Kids in Pain » (SKIP) qui signifie « Des solutions pour les enfants en douleur ».

Nous encourageons tous ceux qui ont un intérêt pour la gestion de la douleur chez les enfants de bien vouloir compléter ce sondage qui ne vous prendra que 5 minutes à remplir.

LIEN VERS LE SONDAGE :  https://surveys.dal.ca/opinio/s?s=45431

Nous utiliserons vos commentaires afin de développer un réseau qui améliorera la gestion de la douleur chez les enfants au Canada et ailleurs !

N’hésitez pas à partager cette publication dans vos réseaux également! Merci pour votre participation ! Vous pouvez également suivre nos progrès sur Twitter : @KidsinPain.

 

#PsBesoinDeFaireMal